ROS1融合基因在非小细胞肺癌靶向治疗中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2017.10.015

摘要/Abstract

摘要： 非小细胞肺癌(NSCLC)的分子靶向治疗已经成为目前医学领域的研究热点，继表皮生长因子受体（EGFR）、鼠类肉瘤病毒癌基因（KRAS）以及间变性淋巴瘤激酶（ALK）等熟知的肿瘤驱动基因被发现之后，越来越多的学者把焦点转移到ROS1融合基因上。ROS1基因编码的蛋白是受体酪氨酸激酶超家族成员之一，对细胞生长和生存起着重要作用。在NSCLC的发生、发展及临床治疗中，ROS1融合基因更是扮演着至关重要的角色。

关键词: 癌, 非小细胞肺, ROS1融合基因, 克唑替尼, 分子靶向治疗

Abstract: The molecular target therapy of nonsmall cell lung cancer (NSCLC) has become a hot research direction in the field of medicine. Following the discovery of wellknown tumordriven genes such as epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene (KRAS) and anaplastic lymphoma kinase (ALK) genes, more and more scholars have shifted focus to ROS1 fusion gene. The protein encoded by ROS1 is a member of the receptor tyrosine kinase super family, and it plays an important role in cell growth and cell survival. ROS1 fusion gene plays a vital role in the occurrence, development and clinical treatment of NSCLC.

Key words: Carcinoma, nonsmallcell lung, ROS1 fusion gene, Crizotinib, Molecular targeted therapy

闯鑫,金波. ROS1融合基因在非小细胞肺癌靶向治疗中的研究进展[J]. 国际肿瘤学杂志, 2017, 44(10): 783-786.

Chuang Xin, Jin Bo. ROS1 fusion gene in targeted therapy of nonsmall cell lung cancer[J]. Journal of International Oncology, 2017, 44(10): 783-786.

参考文献

［1］蔡微菁, 粟波. 非小细胞肺癌的全新靶点ROS1融合基因［J］. 中华肿瘤杂志, 2013, 35(1): 14. DOI: 10.3760/cma.j.issn.02533766.2013.01.001. ［2］ Rikova K, Guo AL, Zeng QF, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer［J］. Cell, 2007, 131(6): 11901203. DOI: 10.1016/j.cell.2007.11.025. ［3］ Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1positive tumors in nonsmall cell lung cancer: identification of a FIGROS1 fusion［J］. Clin Cancer Res, 2012, 18(16): 44494457. DOI: 10.1158/10780432.CCR113351. ［4］ Govindan R, Ding L, Griffith M, et al. Genomic landscape of nonsmall cell lung cancer in smokers and neversmokers［J］. Cell, 2012, 150(6): 11211134. DOI: 10.1016/j.cell.2012.08.024. ［5］ MescamMancini L, Lantuéjoul S, MoroSibilot D, et al. On the relevance of a testing algorithm for the detection of ROS1rearranged lung adenocarcinomas［J］. Lung Cancer, 2014, 83(2): 168173. DOI: 10.1016/j.lungcan.2013.11.019. ［6］ Yasuda H, De FigueiredoPontes LL, Kobayashi S, et al. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1translocated lung cancer［J］. J Thorac Oncol, 2012, 7(7): 10861090. DOI: 10.1097/JTO.0b013e3182570919. ［7］ Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers［J］. J Clin Oncol, 2012, 30(8): 863870. DOI: 10.1200/JCO.2011.35.6345. ［8］朱海波, 徐小玉, 王玲. 克里唑替尼治疗晚期非小细胞肺癌的临床研究进展［J］. 中国肺癌杂志, 2013, 16(6): 321324. DOI: 10.3779/j.issn.10093419.2013.06.09. ［9］宋勇, 杨雯. 2014年晚期非小细胞肺癌内科治疗进展［J］. 解放军医学杂志, 2015, 40(1): 1015. DOI: 10.11855/j.issn.05777402.2015.01.03. ［10］ Goodwin S, Mcpherson JD, Mccombie WR. Coming of age: ten years of nextgeneration sequencing technologies［J］. Nat Rev Genet, 2016, 17(6): 333351. DOI: 10.1038/nrg.2016.49. ［11］ Bos M, Gardizi M, Schildhaus HU, et al. Complete metabolic response in a patient with repeatedly relapsed nonsmall cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib［J］. Lung Cancer, 2013, 81(1): 142143. DOI: 10.1016/j.lungcan.2013.02.018. ［12］ Chiari R, Buttitta F, Iacono D, et al. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization and immunohistochemistrypositive lung adenocarcinoma: a case series［J］. Clin Lung Cancer, 2014, 15(6): 470474. DOI: 10.1016/j.cllc.2014.06.004. ［13］ Kazandjian D, Blumenthal GM, Luo L, et al. Benefitrisk summary of crizotinib for the treatment of patients with ROS1 alterationpositive, metastatic nonsmall cell lung cancer［J］. Oncologist, 2016, 21(8): 974980. DOI: 10.1634/theoncologist.20160101. ［14］ Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in nonsmall cell lung cancer［J］. Cancer Discov, 2013, 3(4): 430443. DOI: 10.1158/21598290.CD120440. ［15］ Ajimizu H, Kim YH, Mishima M. Rapid response of brain metastases to alectinib in a patient with nonsmallcell lung cancer resistant to crizotinib［J］. Med Oncol, 2015, 32(2): 477. DOI: 10.1007/s1203201404777. ［16］ Davare MA, Saborowski A, Eide CA, et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins［J］. Proc Natl Acad Sci USA, 2013, 110(48): 1951919524. DOI: 10.1073/pnas.1319583110. ［17］ Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1rearranged nonsmallcell lung cancer［J］. N Engl J Med, 2014, 371(21): 19631971. DOI: 10.1056/NEJMoa1406766. ［18］ Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: nonsmall cell lung cancer, version 4.2016［J］. J Natl Compr Canc Netw, 2016, 14(3): 255264. ［19］ Awad MM, Katayama R, Mctigue M, et al. Acquired resistance to crizotinib from a mutation in CD74ROS1［J］. N Engl J Med, 2013, 368(25): 23952401. DOI: 10.1056/NEJMoa1215530. ［20］ Sun H, Li Y, Tian S, et al. Ploop conformation governed crizotinib resistance in G2032Rmutated ROS1 tyrosine kinase: clues from free energy landscape［J］. PLoS Comput Biol, 2014, 10(7): e1003729. DOI: 10.1371/journal.pcbi.1003729. ［21］ Davies KD, Mahale S, Astling DP, et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in nonsmall cell lung cancer［J］. PLoS One, 2013, 8(12): e82236. DOI: 10.1371/journal.pone.0082236. ［22］ Yu H, Li Y, Ge Y, et al. Novel 4anilinoquinazoline derivatives featuring an 1adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines［J］. Eur J Med Chem, 2016, 110: 195203. DOI: 10.1016/j.ejmech.2016.01.045. ［23］ Takegawa N, Hayashi H, Iizuka N, et al. Transformation of ALK rearrangementpositive adenocarcinoma to smallcell lung cancer in association with acquired resistance to alectinib［J］. Ann Oncol, 2016, 27(5): 953955. DOI: 10.1093/annonc/mdw032.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[8]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[9]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[10]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[11]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[12]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[13]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[14]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[15]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.